Skinvisible, Inc. (SKVI)

Our latest clients all have the potential to grow significantly in the near and long-term future

Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Oct 05, 2017 7:31 pm

Skinvisible, Inc., through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

- Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
- Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
- Unique formulations are non-drying and provide the ability to control the release of active ingredients.
- Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.

Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Oct 06, 2017 3:50 pm

Skinvisible, Inc. (SKVI) is “One to Watch”

- Patented technology enhances how topical and transdermal drugs and skin care products are delivered
- Polymer delivery vehicle can be tailored to almost any type of molecule including the medicinal components of hemp and marijuana
- 14 patents granted in the U.S. and internationally
- $65 billion market in dermatology, pharmaceutical and other healthcare industries offers strong growth opportunity

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is a Research and Development company whose patented Invisicare® technology can be used to revitalize or create new medical or skincare products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of “gold standard” dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.

Invisicare® is a high performance topical and transdermal delivery system which enhances the delivery of drugs and other ingredients to and through the skin. The key to Skinvisible’s patented technology and trademarked Invisicare® family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Invisicare® can be a key component of life cycle management, extending the life with a new patent-protected product, dramatically expanding the company’s revenue stream.

Independent studies of Invisicare ® have shown the following benefits:

Active ingredients stay on the skin for up to four hours or more and resist wash off and rub off.
Delivery method results in improved efficacy, reduced skin irritation and lower required dosage.
Unique formulations are non-drying and provide the ability to control the release of active ingredients.
Products form a protective barrier, which means normal skin respiration and perspiration occur and the product wears off as part of the skin’s natural exfoliation process.
Terry Howlett, President, founder and CEO of Skinvisible Inc., said the Company has more than 15 years of scientific research and product development experience. All development is conducted using stringent pharmaceutical standards. The Company has licensed a number of its formulations including a prescription hemorrhoid cream in the USA, its anti-aging Kintari® line of products and DermSafe®, its non-alcohol hand sanitizer to a licensee in China. Producing licensed products for the booming cannabis industry is also an important element of the company’s business strategy.

Skinvisible’s foray into the rapidly expanding market for medicinal and recreational cannabis products is already underway with the development of the company’s first hemp-derived CBD (cannabidiol) products. Skinvisible has negotiated an exclusive licensing deal in Canada with Canopy Growth Corporation, one of the world’s leading cannabis companies. As part of the company’s overall growth strategy, Skinvisible is also negotiating with a Licensed Producer in Las Vegas where Skinvisible scientists will develop THC (tetrahydrocannabinol) products for the legal recreational and medical marijuana market for the USA. Notably, Skinvisible is actively pursuing potential licensees through-out the world where medical cannabis is legal. These licensees will have the exclusive right to manufacture and distribute Skinvisible’s cannabis products within their territory.

“We are excited about the results we are already seeing just with our hemp-derived CBD products,” Howlett says. “Our science shows that our CBD products release almost four times that of market leaders and our transdermal product had an 81% penetration rate at 6 hours. These results are significant and provide the difference between ordinary cannabis products and ones enhanced by Invisicare.”

The Company’s business model includes out-licensing its formulations for a development fee, license fee and on-going royalties in addition to selling its Invisicare polymers to its licensees.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Oct 12, 2017 6:17 pm

NetworkNewsBreaks – Why Skinvisible, Inc. (SKVI) is Worth Watching in a $65B Market

Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., is an R&D company offering its patented Invisicare® technology, which can be used to revitalize or create new medical or skincare products, thus enabling companies that license Skinvisible’s formulations to sell their own patented products and ward off generic rivals. A high-performance topical and transdermal delivery system, Invisicare enhances the delivery of drugs and other ingredients to and through the skin utilizing Skinvisible’s innovative formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. An article discussing this reads: “A prescription dermatology product can generate $100 million or more a year, with the potential to lose 50-90% of that revenue when it goes off patent. Preserving that revenue is why the licensing of a product made with Invisicare is a very desirable option for many companies. The Company has developed a pipeline of 40 products using Invisicare, with a primary focus on optimizing the performance and increasing the value of ‘gold standard’ dermatology drugs and licensing them to international and multi-national companies in the pharmaceutical, over-the-counter and cosmeceutical markets.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Oct 16, 2017 4:36 pm

Skinvisible, Inc. (SKVI) Has Been Delivering its Patented Polymer Technology to Pharmaceuticals & Cosmeceuticals for Close to Two Decades

- Topical product technology protected by patents
- Targeting $80 billion global skin care and dermatology market
- Product sales in China

Outsourcing has been the status quo in the pharmaceutical industry since long before the term gained notoriety. Large pharmaceutical and cosmeceutical companies, under pressure from rising R&D costs, have been farming out that part of their businesses for a long time now in an attempt to reduce costs. This approach also has the advantage of offloading the costs of patenting to the outsourcee. To obtain the advantages of adopting new technology, patent protection is vital to avoid copycatting. That is why the technology developed by Skinvisible, Inc. (OTCQB: SKVI), through its wholly owned subsidiary Skinvisible Pharmaceuticals, Inc., has been adopted by pharmaceutical and cosmeceutical companies since 1999. The Las Vegas, Nevada–based R&D company developed Invisicare® technology, which can be used to revitalize or create new medical or skin care products, allowing a company that licenses Skinvisible’s formulations to sell their own patented product and combat generic competitors.

Invisicare is a patented polymer delivery system that improves the delivery of topically applied skin care products, thereby enhancing the efficacy of the active ingredients. The unique process extends the time the product remains active on the skin and is specifically formulated to transport active ingredients that are insoluble in water without using alcohol, silicones, waxes, or other organic solvents.

Products utilizing Invisicare have been effective at bonding active ingredients to the skin for up to four hours and longer. Invisicare is non-occlusive; it allows normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants. When topically applied, products formulated with Invisicare adhere to the skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skin care agents to the skin. This allows enhanced delivery performance for a variety of topicals, resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions that make up Invisicare wear off as part of the natural exfoliation process that removes the skin’s outer layer of cells.

With a $80 billion global dermatology market and a $30 billion global skin care over-the-counter (OTC) market, the patented polymer delivery system for topical products developed by Skinvisible, obviously, has many, many possible applications. The company has already inked an agreement (http://nnw.fm/a1Izk) with a large, well-known Canadian medical marijuana company: the first to attain ‘unicorn’ status in the industry. Under the agreement, the MMJ company will distribute Skinvisible’s topical products in Canada. The agreement covers two distinct product lines made with Skinvisible’s Invisicare technology. Skinvisible will develop unique topical hemp-based products to be launched by Canopy Hemp Corporation in Canada and the United States. In addition, the agreement includes potential cannabis-based topical products using Invisicare® technology when and if federal regulations permit CBD- or THC-infused topical products for sale in Canada.

While it continues to expand its licensing relationships, Skinvisible is developing its own line of OTC products, which is available for out-licensing. The 40+ products include antimicrobial hand sanitizers and skin care products for acne, skin fungi and atopic dermatitis. Skinvisible has also developed its own line of anti-aging products under the Kintari® brand (day cream, night cream, hand & body lotion, sunscreen and DermSafe), all available on www.Kintari.com. Kintari is a wholly owned subsidiary of Skinvisible.

In June 2017, the company announced that it had completed its first international sale of DermSafe® hand sanitizer in China (http://nnw.fm/awjI5) through its agent, InterSpace Global, Inc. The agreement with InterSpace Global facilitates the export of Skinvisible’s OTC products to mainland China, Hong Kong, Macau, Taiwan, Singapore, Malaysia, Thailand and Korea. In the beauty-conscious Chinese diaspora, Skinvisible is on track to repeat its U.S. success story.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Tue Oct 24, 2017 5:20 pm

Skinvisible, Inc. (SKVI) Targets Global Skincare Market Projected to Reach $135B by 2021

Owns patented Invisicare® polymer delivery system, prescription and over-the-counter skincare products formulated with Invisicare
Business model to grow globally by out-licensing its proprietary and patented product line
Developed multiple cannabis-based products with CBD from imported hemp (non-psychoactive), and will continue to develop line utilizing CBD and THC from marijuana
Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market projected to reach $135 billion by 2021 (http://nnw.fm/61ruV). SKVI also sees a worldwide dermatology market now of $80 billion plus a $30 billion worldwide over-the-counter (OTC) market (http://nnw.fm/0NaOC). It has already completed on the development of 40 products, received numerous technology and product patents, and is now ready to monetize its investment. In the US alone, skincare is projected to reach $10.7 billion by 2018 and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021 according to MarketResearch.com (http://nnw.fm/3Uy9z).

It seeks to maximize profits on already-licensed products and grow by adding more licenses to established manufacturers and marketers. Skinvisible has recently formed commercial subsidiaries, Kintari International Inc., along with Kintari USA Inc. and Kintari Canada, Inc. It formed the subsidiaries to bring its cosmeceutical and select OTC products to market.

Skinvisible is a Nevada-based R&D company focused on the licensing of its topical formulations made with its proprietary polymer-based delivery technology Invisicare®. Invisicare is a technology with 14 international patents and is designed to improve the delivery of the active ingredients. Invisicare holds active ingredients on the skin for extended time periods and control their release.

Along with dermatology, the company has also seen a growing demand for topically-delivered cannabis. This is evidenced by its recent announcement with Canopy Growth Corporation in Canada.

The Company in a recent 10Q SEC filing (http://nnw.fm/76cxG) indicated it will continue to out-license its patented prescription and OTC products formulated with Invisicare. Its business model is to increase the value of its product pipeline, boost licensing revenues, capitalize on the success of current licensees, and generate revenue from online and retail sales of its cosmeceutical/OTC line.

The filing added that Skinvisible has named David St. James to the board of directors. An inventor and businessman based in Las Vegas, he is deemed qualified in recognition of his technical abilities and management skills.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Oct 26, 2017 6:25 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Takes Aim at the Global Skincare Market

Research and development company Skinvisible, Inc. (OTCQB: SKVI) has set its sights on the burgeoning global markets for skincare, dermatology and over-the-counter products. An article discussing this reads: “Skinvisible, Inc. (OTCQB: SKVI) is targeting a global skincare market that's projected to reach $135 billion by 2021 (http://nnw.fm/61ruV). SKVI also sees a worldwide dermatology market of $80 billion, plus a $30 billion worldwide over-the-counter (OTC) market (http://nnw.fm/0NaOC). It has already completed the development of 40 products, received numerous technology and product patents and is now ready to monetize its investment. In the U.S. alone, skincare is projected to reach $10.7 billion by 2018, and the global skincare market is seen growing at a compound annual growth rate (CAGR) of 3.8% from 2016-2021, according to MarketResearch.com (http://nnw.fm/3Uy9z).”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Nov 03, 2017 4:08 pm

NetworkNewsBreaks – Skinvisible, Inc.’s (SKVI) Invisicare Technology Tackles Dermatology, CBD Markets

Research and development company Skinvisible, Inc. (OTCQB: SKVI) has developed Invisicare® technology, a patented polymer delivery system that improves the delivery of topically applied skin care products by enhancing the effectiveness of the active ingredients. Skinvisible out-licenses its formulations, enabling companies like Canopy Hemp Corporation to bring their own patented products to market and combat generic competitors. An article discussing this reads: “With a $80 billion global dermatology market and a $30 billion global skin care over-the-counter (OTC) market, the patented polymer delivery system for topical products developed by Skinvisible, obviously, has many, many possible applications. The company has already inked an agreement (http://nnw.fm/a1Izk) with a large, well-known Canadian medical marijuana company: the first to attain ‘unicorn’ status in the industry. Under the agreement, the MMJ company will distribute Skinvisible’s topical products in Canada. The agreement covers two distinct product lines made with Skinvisible’s Invisicare technology. Skinvisible will develop unique topical hemp-based products to be launched by Canopy Hemp Corporation in Canada and the United States. In addition, the agreement includes potential cannabis-based topical products using Invisicare® technology when and if federal regulations permit CBD- or THC-infused topical products for sale in Canada.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Nov 06, 2017 5:58 pm

Skinvisible, Inc.’s (SKVI) Patented Polymer Delivery Technology Could Take CBD Products to the Next Level

- Skinvisible already develops hemp-based products and is expanding its product line of cannabis-based topical product market
- Research verifies its Invisicare® technology improves the penetration rate and boosts the availability of the cannabis ingredients in both topical and transdermal products
- Skinvisible has entered a strategic partnership with Canopy Growth Corporation for the sale of its product formulations in the Canadian market

Invisicare®, a proprietary topical drug delivery technology developed by Skinvisible, Inc. (OTCQB: SKVI), has a potentially wide range of applications in the cannabis market. The technology improves the delivery of pharmaceutical and medicinal compounds to and through the skin, which can increase the effectiveness of the various medicinal components of cannabis, such as the cannabidiol (CBD).

The patented polymer technology has been used in cosmeceutical, over-the-counter and pharmaceutical products for nearly two decades. On September 28, 2017, Skinvisible signed an exclusive agreement with Canopy Growth Corporation for the purpose of increasing its reach to Canada and establishing its position on the cannabis product markets. The definitive licensing agreement for patented topical formulations by Skinvisible puts emphasis on two product lines – unique topical hemp-based products that will be launched in Canada and the future development of cannabis-based topical products.

Nevada-based Skinvisible has been actively seeking licensees for its cannabis formulations made with its patented Invisicare® delivery system in the 29 US states that have approved medical marijuana. These licensees will gain the exclusive right to manufacture and distribute the Invisicare formulated cannabis products.

Through its partnership with Canopy Growth, Skinvisible has its first licensee exclusively for the Canadian market. Regulations pertaining to Cannabis products sold in Canada are quite different from the U.S. legislative framework. Only one license is required for distribution, which simplifies the administrative aspect of entering the market. In addition, the Canadian cannabis market is expanding rapidly. Statista.com projects that the medical marijuana market in Canada will grow from 49 million Canadian dollars in 2015 to 1,146 million dollars in 2020 (http://nnw.fm/uDb9A). Of these, 653 million dollars will come from dried marijuana products and 493 million dollars will come from oils.

Skinvisible is a confident market player that has over 15 years of experience in product development. Stringent pharmaceutical standards are applied to the creation of every new product. According to Skinvisible President Terry Howlett, this experience has proven to be invaluable for the company’s entry into the cannabis market. Howlett said that the test results the company is already getting with hemp-based products are surpassing expectations.

Company research suggests that because of Invisicare®, Skinvisible’s hemp-derived CBD products release almost four times the active ingredients found in other leading topical products on the market. The penetration rate of the Skinvisible transdermal products was 81 percent. These results show just how different Invisicare® makes the topical options from other CBD products out there, Howlett concluded.

Apart from targeting the U.S. and Canadian markets, Skinvisible is also looking to expand to Europe, Latin America and Australia in the near future. The move is in line with the latest tendencies pertaining to the global growth of the CBD market. The Hemp Business Journal reports that CBD product sales went up 1,710 percent on an annual basis in 2016 (http://nnw.fm/NVt6r). According to experts quoted in the report, word of mouth promotion has been one of the driving factors for the positive trend.

Long-term predictions are also bold. The cannabis market could grow by 700 percent by 2020 (http://nnw.fm/H5Dx3). This means that sales by the year will reach 2.1 billion dollars, of which 450 million dollars will be derived from hemp-based products.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Wed Nov 08, 2017 6:30 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Develops Hemp-based Products with an Enhanced Delivery System

Skinvisible, Inc.’s (OTCQB: SKVI) proprietary topical drug delivery technology, Invisicare®, improves the delivery of pharmaceutical and medicinal compounds to and through the skin. The company develops hemp-based products and recently expanded its product line to the enter the cannabis-based topical product market. An article discussing this reads: “The patented polymer technology has been used in cosmeceutical, over-the-counter and pharmaceutical products for nearly two decades. On September 28, 2017, Skinvisible signed an exclusive agreement with Canopy Growth Corporation for the purpose of increasing its reach to Canada and establishing its position on the cannabis product markets. The definitive licensing agreement for patented topical formulations by Skinvisible puts emphasis on two product lines – unique topical hemp-based products that will be launched in Canada and the future development of cannabis-based topical products.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Nov 09, 2017 7:00 pm

Could Skinvisible (SKVI) Have the Answer to a Potential New Global Flu Pandemic?

- Skinvisible Pharmaceuticals, Inc. is making confident steps toward the large-scale distribution of its hand sanitizer in China
- Clinical studies show that frequent hand sanitization is the only effective non-pharmaceutical measure for influenza prevention
- Worries about the spread of avian influenza and its high mortality rate have triggered the introduction of more rigorous prophylactic measures and market growth

H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://nnw.fm/Aj1UB). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.

As winter approaches, researchers warn that the risk of flu viruses spreading increases. H7N9 infections have been sporadic so far, but the virus has been mutating (http://nnw.fm/l1IzO). This would be its sixth year of existence, and, over this period of time, avian influenza has had a mortality rate of 36 percent among 1,562 lab-confirmed infections. The fifth wave of the viral infection (starting in 2017) has been the deadliest one yet. Out of 764 infected individuals, 250 died because of the virus.

Virus mutations, more serious epidemics and their consequences are making researchers work hard on the creation of flu prevention products. Influenza vaccines are becoming more popular than ever before, with a projected growth in the U.S. from 147.8 million doses in 2016 to 179 million doses in 2017 (http://nnw.fm/IQ9yA). The current value of the market is estimated at $4 billion.

Apart from vaccination, the use of the right personal hygiene products is another highly effective way to prevent the spread of flu viruses, including H7N9. According to a report presented in the BMC Public Health Journal, frequent hand washing and sanitization (at least five times per day) is the only non-pharmaceutical prophylactic measure that is a statistically-significant protective factor in the case of pediatric influenza (http://nnw.fm/a4t7X).

Hand sanitizers like Skinvisible’s DermSafe could be one of the answers when it comes to influenza prevention. Independent studies of the product suggest that DermSafe kills germs immediately upon application, and it also provides four additional hours of protection upon topical use. In addition to its powerful anti-bacterial/viral properties, DermSafe is free from alcohol. This means that it doesn’t have a drying effect, and it feels pleasant on the skin.

DermSafe’s formulation features chlorhexidine gluconate in a four-percent concentration. This ingredient has proven its ability to kill both gram-positive and gram-negative bacteria, as well as viruses. It also offers long-lasting protection from germs when human skin comes in contact with hard surfaces. Through clinical tests, it’s been proven that the active ingredient in DermSafe is effective against H7N9, as well as H1N1 – the swine flu virus.

Since DermSafe is approved for sale by Health Canada, prior to its product launch in China, DermSafe was used by the Canadian Olympic team during the games in Rio. The Olympic team was capable of successfully addressing concerns stemming from water quality through the use of the hand sanitizer. The Canadian Olympic team will also be protected by DermSafe in February 2018 at the Winter Olympic Games in South Korea.

Skinvisible Pharmaceuticals is looking for opportunities to expand the distribution of DermSafe globally. In 2013, the Company obtained registration rights for DermSafe in Belgium. Through this designation, the hand sanitizer can be registered and distributed in most EU countries. The larger long-term strategy includes the effective distribution of the company’s product globally.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Thu Nov 16, 2017 7:56 pm

NetworkNewsBreaks – Skinvisible (SKVI) Inks Licensing Agreement for Distribution of Topical Cannabis Products in Select U.S. Markets

Pharmaceutical solutions researcher Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) this morning said its Ovation Science subsidiary has reached a licensing agreement with Cannabiniers, a subsidiary of Lighthouse Strategies, LLC, to distribute Skinvisible’s patented Invisicare transdermal drug-delivery technology to select markets in the United States where medical cannabis products have been legalized."We are excited to have Cannabiniers as a partner in the U.S. cannabis market. They are branding experts and have the vision and infrastructure to take Ovation's cannabis products across the United States," Skinvisible President Terry Howlett stated in the press release. "Leveraging Cannabiniers branding strategies, we have the ability to enter these markets and provide consumers with an exceptional variety of topical and transdermal products backed by science and formulated with patented technology.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Nov 20, 2017 5:34 pm

NetworkNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Could Have the Solution to the Flu Epidemic

Skinvisible Pharmaceuticals (OTCQB: SKVI) is a topical and transdermal product development company with a proprietary drug delivery system, Invisicare, that improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically, CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). The key to Skinvisible's patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Applications of this novel technology are discussed in a recent article that says in part, “H7N9 (a type of avian influenza virus) could be the one to cause the next global flu pandemic, the World Health Organization (WHO) warns (http://nnw.fm/Aj1UB). Luckily, the flu prophylactic market is already offering some adequate options, and DermSafe® by Skinvisible, Inc. (OTCQB: SKVI) subsidiary Skinvisible Pharmaceuticals, Inc. is one of them. In June, Skinvisible announced the first international sale of DermSafe in China – a country that’s known to have the first reported cases of human avian influenza infections.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Tue Nov 21, 2017 5:15 pm

Skinvisible, Inc. (SKVI) Subsidiary Inks License Agreement for US Distribution of Topical Cannabis Products

- Announces formation of new Canadian subsidiary Ovation Science Inc.
- Agreement forged with Lighthouse Strategies, LLC, regarding exclusive use of patented topical and transdermal formulations in select U.S. markets
- Licensing agreement recently made with Canopy Growth Corp. for exclusive rights in Canada

Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) announced on November 16 that it has formed a new subsidiary, Ovation Science Inc., and that Ovation has inked a definitive license agreement with Lighthouse Strategies, LLC (http://nnw.fm/GJlS6). The agreement, made through Ovation, stipulates that Lighthouse will have exclusive use of the company’s patented topical and transdermal formulations for select markets in the United States.

Via Lighthouse’s technology division and in collaboration with the San Diego-based Advocacy Research Center (ARC), Lighthouse plans to introduce Ovation’s topical and transdermal products formulated with its patented drug delivery system, Invisicare®. In doing this, Lighthouse intends to foster the development of safe, healthy and lifestyle-integrated treatments coupled with accurate time-released dosing.

Cannabiniers, an established technology and brand management company and Lighthouse subsidiary, will conduct the national distribution of products and brands. Cannabiniers is a pioneer in the cannabis industry, offering revolutionary, patented technologies. In distributing Ovation’s topical products in the U.S., Cannabiniers will leverage its branding prowess and its expertise in local, regional and national cannabis markets.

In working with Ovation, Cannabiniers further aims to normalize consumption and help integrate cannabis into the daily lives of patients and consumers—something Cannabiniers has done with its own brands.

Ovation Science Inc. has been founded in order to better serve the needs of licensees, as well as to focus on specific product development within the cannabis market. This subsidiary has been granted the exclusive global right to all products formulated using Skinvisible’s patented Invisicare® technology with cannabis and hemp seed oil.

In September 2017, Skinvisible also forged a licensing agreement with Canopy Growth Corp., the largest cannabis company in the world, for exclusive rights for Canada and the right of first refusal in other countries outside Canada and the U.S. where cannabis is legal. Ovation has been assigned this license agreement with Canopy.

Skinvisible’s game-changing Invisicare® platform is a patented polymer technology that enhances topical and transdermal drug delivery. When used in topical and transdermal cannabis products, this technology enables improved release and penetration of the product.

Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries.

Like the blockchain and cryptocurrency market, the cannabis market is exploding throughout the world, and Skinvisible’s pioneering technology is poised to be a game-changer for various companies in this space.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Nov 27, 2017 6:15 pm

NetworkNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Enters Non-Binding Term Sheet for Proposed Merger with Quoin Pharmaceuticals

Skinvisible Pharmaceuticals (OTCQB: SKVI) has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd. per the company’s announcement this morning. The completion of the proposed merger is subject to the negotiation of a definitive agreement and other customary closing conditions including tax, accounting, legal, and regulatory conditions. The new company would continue trading on the OTCQB market under the name Quoin Pharmaceuticals Inc. and is expected to have a robust product portfolio addressing major unmet medical needs. Post-merger, the new company will be 72.5% owned by Quoin shareholders and Skinvisible shareholders will own 27.5%, prior to any effect from financing activities. The company anticipates the merger will take place in early 2018. "This potential merger with Quoin is the best option for our company and may offer significant value to shareholders as Quoin commences and progresses with its clinical development plans. We look forward to working with Quoin's team of experts to maximize the product development opportunities," Skinvisible president Terry Howlett stated in the news release.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Mon Dec 04, 2017 5:09 pm

Skinvisible, Inc.’s (SKVI) Topical Drug Delivery System Set to Enjoy New Licensing Opportunities

- Proven patented polymer drug delivery technology
- Global topical drug delivery market set for CAGR of 9.2% over next 7 years
- Strategy to derive revenues from royalties and other licensing fees

Skinvisible, Inc. (OTCQB: SKVI) is set for a business renaissance in the coming years. The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good news for Skinvisible, which derives part of its revenues from royalties and other product licensing fees. The Company is already having success in this area. It has announced a number of licensing agreements. As the global topical market continues its robust growth, Skinvisible’s licensing business appears more than skin deep.

The glowing Global Topical Drug Delivery Market 2017-2024 report by Data Bridge Market Research details some of the factors expected to drive market growth (http://nnw.fm/o7mJx). In some instances, topical technologies have exhibited superior therapeutic outcomes, by improving the delivery of active ingredients to a targeted site, in responding to inter-and intra-patient differences without fluctuations in drug levels, and in higher levels of patient compliance.

Although the Data Bridge survey covered all skin-administered delivery systems, the term “topical” is also applied more narrowly to a medication intended to have an effect at the site of application. Such topical applications typically do not result in significant drug concentrations in the blood and other tissue and cause fewer adverse reactions. They are contrasted with transdermal medications, which are absorbed through the skin or mucosal membranes, and are intended to have an effect in areas of the body away from the site of application. Transdermal administration is an excellent method to use when a patient is unable to swallow or for medications that are significantly metabolized by the liver, and is frequently utilized for anti-nausea drugs, hormone replacement therapy, and generalized pain. In addition to these technical factors, an increasing aging population and the growing prevalence of skin related ailments will undoubtedly contribute to topical market growth. With such rapid market expansion in the offing, drug marketers will have to rely on R&D companies like Skinvisible and their novel delivery technologies.

The backbone of Skinvisible’s licensing strategy is its Invisicare® technology, which is now truly time-tested after 15 years’ utilization in developing a portfolio of over 40 prescription, over-the-counter (OTC) and cosmeceutical products. Invisicare is a high performance polymer technology that improves how products are delivered to the skin. It improves the release of active ingredients, increases the binding of the product to the skin, improves the stabilization of ingredients and can improve efficacy, safety and consumer satisfaction. Skinvisible’s Invisicare technology enjoys comprehensive patent protection. A prescription dermatology product can generate $100 million or more a year.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Tue Dec 05, 2017 6:47 pm

Skinvisible, Inc. (SKVI) Maximizes Product Development Opportunities with Global Goals

- Targeting unmet medical needs with proprietary topical formulations
- License-based business model translates to worldwide opportunities
- Patented Invisicare™ technology offers enhanced drug delivery system

Global skincare market projected to reach $135 billion by 2021
Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), continues to add significant value to its core business model with several key movements involving a proposed merger, new licensing agreements and formation of a specialized subsidiary.

The Company’s November 27 announcement that it has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd., pending customary closing conditions, melds industry veterans committed to developing products which address major societal issues with Skinvisible’s team of R&D scientists. Quoin’s two lead products are targeting crises such as the opioid epidemic and the military veteran suicide rate that result in the death of almost 120 people in the United States every day (http://nnw.fm/maKM8).

Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The Company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.

There’s plenty of room for Skinvisible’s proprietary technology within the skincare, dermatology and over-the-counter cosmeceutical markets, as evidenced by numerous reports from MarketResearch.com which state the global skincare market alone is projected to reach $135 billion by 2021 (http://nnw.fm/Lr1fL).

In September, Skinvisible announced it had signed a licensing agreement with Canopy Growth Corporation, the world’s largest cannabis company. This was followed in November when Skinvisible reported it had formed a new subsidiary, Ovation Science Inc., for the purpose of better serving the needs of licensees, as well as to focus on specific product development within the cannabis market. In fact, Ovation Science has already reached a licensing agreement with Cannabiniers, a subsidiary of Lighthouse Strategies, LLC, to distribute Skinvisible’s patented cannabis products to select markets in the United States where medical cannabis products have been legalized (http://nnw.fm/3lPb0). Invisicare’s game-changing technology enhances topical and transdermal drug delivery, enabling improved release and penetration of the product.

Another milestone was reached in June of this year when the Company first sold its hand sanitizer DermSafe product in China. Clinical studies show that frequent hand washing and sanitization is an effective way to help prevent the spread of flu viruses, including some of the more virulent forms now being seen around the world (http://nnw.fm/Feb9M). Interestingly, DermSafe was used by the Canadian Olympic team during the games in Rio, addressing concerns stemming from poor water quality through the use of the hand sanitizer. The Canadian Olympic team will also be protected by DermSafe in February 2018 at the Winter Olympic Games in South Korea.

For more information, visit the company’s website at www.Skinvisible.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Sat Dec 09, 2017 7:59 am

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Poised for Growth More than Skin Deep

Skinvisible (OTCQB: SKVI) is poised for growth in the booming global topical drug delivery market. A recent article highlights the company’s positioning, stating, “The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good news for Skinvisible, which derives part of its revenues from royalties and other product licensing fees. The Company is already having success in this area. It has announced a number of licensing agreements. As the global topical market continues its robust growth, Skinvisible’s licensing business appears more than skin deep.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Wed Dec 13, 2017 6:43 pm

New Exclusive Licensing Agreement with Cannabiniers, Conducted via Lighthouse Strategies with Skinvisible (SKVI) Subsidiary

- Cannabis industry pioneer Cannabiniers will distribute treatments utilizing Invisicare®, a patented polymer delivery system
- Agreement marks continued growth for Skinvisible’s subsidiary Ovation Science Inc.
- Patented delivery technology enables improved controlled release of topically applied products

Research and development company Skinvisible, Inc. (OTCQB: SKVI) has announced that its subsidiary Ovation Science Inc. has forged a definitive license agreement with Lighthouse Strategies LLC, through its multifaceted cannabis technology and brand management company Cannabiniers, to utilize the Company’s products formulated with its patented pharmaceutical polymer in serving the U.S. cannabis market (http://nnw.fm/3kZGm).

The Lighthouse agreement grants the company exclusive use of Ovation’s new patented topical and transdermal formulations for improved delivery of ingredients in select markets within the United States. This latest agreement is yet another mark of Ovation’s expansion, which has included another recently signed licensing agreement granting Canopy Growth Corp. exclusive rights to Ovation’s cannabis formulations in Canada (http://nnw.fm/l60IQ).

As part of the agreement via Lighthouse, and in cooperation with the Advocacy Research Center, Cannabiniers will distribute cannabis-based treatments utilizing Ovation’s patented technology through its national manufacturing and distribution channels. In distributing these treatments throughout the U.S., Cannabiniers will help foster the development of healthy, safe, lifestyle-centered topical and transdermal cannabis treatments that feature the added asset of accurate time-released dosing.

Cannabiniers’ goal is to standardize cannabis use and foster its integration into the daily lives of patients and consumers—something the company has achieved with its own current brands and now intends to do with Ovation’s topical products, which feature a patented and game-changing delivery technology.

These products will initially be released through Silver State Wellness and San Diego ReLeaf, which are licensed marijuana cultivators and manufacturers of infused products servicing Nevada and California. Ovation’s technology will enable these entities to offer unique topical and transdermal cannabis products that let individuals treat themselves in a comfortable and reliable way while maintaining their everyday lifestyles.

Skinvisible is an R&D company engaged in licensing its proprietary formulations made with Invisicare®, which is the company’s patented polymer delivery system that offers life-cycle management and distinctive enhancements for topically delivered products. Invisicare uniquely allows controlled release of active ingredients and the ability to hold these ingredients on the skin for extended time periods.

Ovation Science is a Canadian subsidiary of Skinvisible holding all the rights to the Company’s cannabis formulations.

For more information, visit the company’s websites at www.Skinvisible.com or www.Invisicare.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: Skinvisible, Inc. (SKVI)

Postby QualityStocks » Fri Dec 15, 2017 4:58 pm

NetworkNewsBreaks – Skinvisible, Inc. (SKVI) Advances Invisicare Delivery System

Topical and transdermal product development company Skinvisible (OTCQB: SKVI) is targeting the pharmaceutical industry with its proprietary drug delivery system, Invisicare. Invisicare improves the delivery of ingredients to and through the skin. An article discussing this reads: “Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 1123
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron